Home›Clinical trials›Arizona

GLP-1 clinical trials in Arizona: 21 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

21 GLP-1 clinical trials are recruiting at 57 sites in 14 cities across Arizona. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Arizona

  1. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06857942.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    10 sites in Arizona
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale. 602-386-4971
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler, Chandler. 480-443-8400
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff, Flagstaff. 928-666-3772
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert, Gilbert. 480-443-8400
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale. 602-386-4969
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa, Mesa. 480-626-6637
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV, Phoenix. 480-626-6637
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City, Sun City. 602-386-4970
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson, Tucson. 520-867-6906
    • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast, Tucson. 520-849-8753

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Arizona

    • HonorHealth Research & Innovation Institute, Scottsdale. 480-323-1046

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Fibrosis Lessens After Metabolic Surgery

    Phase 4. The Cleveland Clinic plans to enroll 120 participants.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD) with liver scarring (fibrosis), BMI 35+.

    1 site in Arizona

    • Banner Health Center, Phoenix

    NCT06374875 on ClinicalTrials.gov. See whether you qualify.

  1. A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    The registry lists a near-identical study as NCT06864026.

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Arizona

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    6 sites in Arizona
    • The Institute for Liver Health II dba Arizona Clinical Trials - Chandler, Chandler
    • Spectrum Research Institute, Gilbert
    • The Institute for Liver Health II dba Arizona Liver Health - Peoria, Peoria. 480-470-4000
    • Epic Medical Research-Sun City, Sun City
    • Del Sol Research Management, LLC, Tucson. 520-257-3881
    • The Institute for Liver Health II dba Arizona Clinical Trials - Tucson, Tucson

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    5 sites in Arizona

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    5 sites in Arizona

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    4 sites in Arizona

    • Mission Research Institute - Gilbert, Gilbert. 833-602-2368
    • Helios Clinical Research - Paradise Valley, Paradise Valley. 833-602-2368
    • Arizona Liver Health - Peoria 85381, Peoria. 833-602-2368
    • Helios Clinical Research - Phoenix, Phoenix. 833-602-2368

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    3 sites in Arizona

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    3 sites in Arizona

    • Research Site, Mesa
    • Research Site, Phoenix
    • Research Site, Tempe

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

The other 11 studies recruiting in Arizona

  1. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in Arizona

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Arizona

    • Kailera Clinical Site, Glendale
    • Kailera Clinical Site, Phoenix

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Arizona

    • Elligo Health Research Inc, Gilbert
    • Velocity Clinical Research-Phoenix, Phoenix

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    2 sites in Arizona

    • Arizona Clinical Trials, Chandler
    • Epic Medical Research - Sun City, Sun City

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 medicine, semaglutide, can help people with atrial fibrillation lose weight.

    Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

    Phase 3. University of Chicago plans to enroll 200 participants.

    Who can join. Adults 18 to 75, have obesity or are overweight, BMI 30+.

    1 site in Arizona

    • The University of Arizona College of Medicine- Phoenix, Phoenix. 602-521-3090

    NCT06499857 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Arizona

    • University of Arizona, Tucson

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    1 site in Arizona

    • Urologic Surgeons of Arizona, Mesa

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  8. A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    4 sites in Arizona

    • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
    • HOPE Research Institute, Phoenix
    • Headlands Research - Scottsdale, Scottsdale. 480-725-8708
    • The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson. 480-470-4000

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  9. A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Arizona

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  10. A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Antag Therapeutics plans to enroll 150 participants.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    1 site in Arizona

    NCT07724340 on ClinicalTrials.gov. See whether you qualify.

  11. A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight

    Phase 1. Terrestrial Bio, Inc plans to enroll 62 participants.

    Who can join. Adults 18 to 60, have obesity or are overweight, BMI 25+.

    1 site in Arizona

    NCT07673900 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Check price →

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.